SkinBioTherapeutics PLC Human study commenced (1789B)
September 19 2018 - 1:00AM
UK Regulatory
TIDMSBTX
RNS Number : 1789B
SkinBioTherapeutics PLC
19 September 2018
SkinBioTherapeutics plc
Human study commenced
Manchester, UK - 19 September 2018 - SkinBioTherapeutics plc
(AIM: SBTX, the "Company"), a life science company focused on skin
health, confirms that it has commenced its human study being
carried out on its SkinBiotix(R) technology.
There are three elements to the human study: the first, already
underway, is to assess skin irritancy; the second, due to commence
on 20 September 2018, is to assess moisturisation potential; and
the third is to assess the technology's impact on the barrier
function. This third element of the study, for which the Company
has now received final ethics approval, has been rescheduled to
commence in November due to capacity issues within the clinical
research organisation.
Study one is a skin irritancy test using different
concentrations of SkinBiotix(R) in the cream formulation. Five
different concentrations of the technology will be compared with
the base formulation (i.e. containing no SkinBiotix(R)) and an
existing marketed dermatological cream. Thirty volunteers will be
assessed for irritancy at various time points up to 72 hours. The
results are expected in October 2018.
Study two is an evaluation of the moisturisation potential of
the SkinBiotix(R) cream formulation compared to the base
formulation. The study will assess 20 participants, with
approximately a 12 hour treatment period for each volunteer. The
results are expected in October 2018.
Study three is a test to determine whether the positive impact
of the technology on the skin's barrier function, which has been
demonstrated in laboratory studies, is replicated in human
volunteers. The Company has now received final ethics approval for
the commencement of this study. The study will be conducted with
120 female volunteers with self-assessed 'dry skin'. The first 20
volunteers will be treated in November 2018 with the remaining 100
volunteers treated in January 2019. Data on the first 20 volunteers
is expected to be available in December 2018 with the full read out
on all 120 volunteers available during Q1 2019.
Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:
"I am delighted that we now have all three aspects of our human
study scheduled. Data from the two initial tests is expected in
October 2018, and data from the third, larger test, is expected in
Q4 2018 and Q1 2019. We hope that these results will provide
additional proof of the SkinBiotix(R) technology's efficacy and
enable us to continue to pursue commercial discussions".
-ENDS-
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468
Dr. Cath O'Neill, CEO 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Tony Rawlinson / Sandy Jamieson / Richard
Nash
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3621
Ben Turner / James Pope 4120
Northland Capital Partners (Joint Broker)
Tom Price Tel: +44 (0) 20 3861
6625
Instinctif Partners (Media Relations) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Deborah Bell 2020
SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLPMRTMBTBBJP
(END) Dow Jones Newswires
September 19, 2018 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024